Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial

This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This article reviews treatment options for androgenetic alopecia and suggests that therapy should be personalized and targeted at various pathophysiological aspects, but reports no new clinical findings.

This review discusses the role of Prostaglandin D2 and its synthase in androgenetic alopecia but reports no new clinical findings, suggesting pathways for future therapeutic development.

This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.

This study found that PGD2 inhibits hair follicle regeneration in mice through the Gpr44 receptor, suggesting that blocking PGD2 or Gpr44 may enhance skin regeneration after wounds.

This study found that bimatoprost stimulated hair growth in both human scalp follicle cultures and mouse pelage in vivo, suggesting it might offer a promising treatment for scalp alopecias.

PGD2 stops hair growth and is higher in bald men with AGA.

This study found that daily oral finasteride may increase hair count and improve hair appearance assessments in men with androgenetic alopecia, but it also appears to raise the risk of sexual dysfunction.

This article reviews existing treatments for male-pattern hair loss, noting that while they can slow progression, they generally achieve only partial hair regrowth.

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

This article reviews the clinical, psychological, and management aspects of androgenetic alopecia in men, stating that it can be effectively managed by generalist clinicians with pharmacotherapy and surgical advancements.

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.

This study found that latanoprost induces significant growth and pigmentation of lashes and ancillary hairs, with effects mirroring both brief and chronic treatments observed in patients and animal models.

This study found that finasteride at 1 mg/day was the most effective dose for treating male pattern hair loss, with similar efficacy to 5 mg/day and better results than lower doses.

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.

Hair loss can cause low self-esteem, anxiety, and depression in men.